Survey on the worldwide availability and affordability of the ILAE Task Force on Access to Treatment

Epilepsia

63, 335-351

DOI: 10.1111/epi.17155

Citation Report

#	Article	IF	CITATIONS
1	Seizure remission rates remain low in a resource-limited country, a multicentre comparison study in Malaysia. Journal of Clinical Neuroscience, 2022, 102, 60-64.	1.5	2
2	An LC–ESI–MS/MS assay for the therapeutic drug monitoring of 15 antiseizure medications in plasma of children with epilepsy. Biomedical Chromatography, 2022, 36, .	1.7	6
4	Treatment gaps in epilepsy. , 0, 2, .		1
5	Challenges for Low <scp>Middleâ€Income</scp> People with Epilepsy during the Covidâ€19 Pandemic <i>Lessons Learnt, Call for Action</i> . Epilepsia Open, 0, , .	2.4	1
6	Incidence of and predictors for antiseizure medication gaps in Medicare beneficiaries with epilepsy: a retrospective cohort study. BMC Neurology, 2022, 22, .	1.8	3
7	Best-worst scaling preferences among patients with well-controlled epilepsy: Pilot results. PLoS ONE, 2023, 18, e0282658.	2.5	1
8	Epilepsy in Niger: An overview of the current situation. Epilepsia Open, 2023, 8, 278-284.	2.4	1
9	Affordability of newer antiseizure medications in Asian resourceâ€limited countries. Epilepsia, 2023, 64, 2116-2125.	5.1	1
10	Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to antiâ€seizure medication. American Journal of Medical Genetics, Part A, O, , .	1.2	O
11	The impact of a newly established specialized pediatric epilepsy center in Tanzania: An observational study. Epilepsy and Behavior, 2023, 148, 109454.	1.7	0
12	What are the considerations when initiating treatment for epilepsy in children?. Expert Review of Neurotherapeutics, 2023, 23, 1081-1096.	2.8	0